Add Drug To My List Compare to related Drugs View/edit/Compare drugs in my list
Select the drug indication to add to your list
KAYEXALATE
Poisoning/overdose  Only 4 drugs may be compared at once
Generic Name and Formulations:
Sodium polystyrene sulfonate; pwd; sodium content 4.1mEq/g.
Company:
Covis Pharmaceuticals, Inc.

Select therapeutic use: Poisoning/overdose
Indications for KAYEXALATE:
Hyperkalemia.

Adult:
See literature. Oral: 15g 1–4 times daily, as a susp. Rectal enema: 30–50g in 100mL every 6 hrs.

Children:
See literature. Use 1g per 1mEq of potassium as basis of calculation.

Contraindications:
Hypokalemia. Obstructive bowel disease. Neonates.

Warnings/Precautions:
Hypokalemia. Monitor electrolytes, ECG. Hypernatremia. CHF. Hypertension. Edema. Risk of constipation/impaction (eg, history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, bowel obstruction); discontinue if significant constipation develops. Monitor for intestinal necrosis (esp. in children). Pregnancy (Cat.C). Nursing mothers.

Interactions:
Avoid non-adsorbable cation donating antacids and laxatives (eg, magnesium hydroxide, aluminum hydroxide). Sorbitol may cause intestinal necrosis (concomitant use not recommended). Digoxin toxicity potentiated by hypokalemia. Reduces absorption of thyroxine, lithium.

Pharmacological Class:
Cation exchange resin.

Adverse Reactions:
GI irritation/ulceration/necrosis, sodium retention, hypokalemia, hypocalcemia, hypomagnesemia, fecal impaction, ischemic colitis.

How Supplied:
Jar (453g)—1